129 - Age at Diagnosis, Glycemic Control and Responses to Oral Blood Glucose Lowering Drugs in Type 2 Diabetes: A Population-Based Study
Calvin Ke(Chinese University of Hong Kong), Andrea O. Y. Luk(Chinese University of Hong Kong), Elaine Chow(Chinese University of Hong Kong), Alice P.S. Kong(Chinese University of Hong Kong), Eric S. H. Lau(Chinese University of Hong Kong), Juliana C.N. Chan(Chinese University of Hong Kong), Ronald C.W. Mawing-Yee So, Thérèse A. Stukel(University of Toronto), Baiju R. Shah(Sunnybrook Health Science Centre)
Cited by 0
Related Papers
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2017|2.1k
Genome-wide trans-ancestry meta-analysis provides insight into the genetic architecture of type 2 diabetes susceptibility
|Nature Genetics|2014|1.1k
A variant in CDKAL1 influences insulin response and risk of type 2 diabetes
|Nature Genetics|2007|1.1k
Type 2 diabetes in East Asians: similarities and differences with populations in Europe and the United States
|Annals of the New York Academy of Sciences|2013|813
Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis
|The Lancet Diabetes & Endocrinology|2017|591